A Phase 1/2 dose escalation and dose expansion study of BA3011 alone and in combination with Nivolumab in adult and adolescent patients 12 years and older with advanced solid tumors

Protocol No
BIOATLA-BA3011-001
Principal Investigator
John Charlson
Phase
I/II
Summary
The purpose of this study is to learn about the safety and effectiveness of an experimental drug called Mecbotamab Vedotin (BA3011) on a variety of cancers that have tested positive for the AXL protein. This study is the first time the Mecbotamab Vedotin has been tested in humans.
Description
The purpose of this study is to learn about the safety and effectiveness of an experimental drug called Mecbotamab Vedotin (BA3011) on a variety of cancers that have tested positive for the AXL protein.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category